2019

December 23, 2019
Sanofi commences tender offer for acquisition of Synthorx, Inc.
December 10, 2019
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
December 10, 2019
Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
December 9, 2019
Sanofi CEO unveils new strategy to drive innovation and growth
December 9, 2019
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
November 4, 2019
Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
November 4, 2019
Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
October 31, 2019
Sanofi Q3 well on track
October 31, 2019
Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
October 29, 2019
Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
October 15, 2019
Exploring the Expansion of Sanofi's Framingham Manufacturing Site
October 1, 2019
Sanofi : Availability of the Pre-quarterly Results Communication
September 30, 2019
Sanofi's Jevtana® (cabazitaxel) becomes a Breakthrough Success in Prostate Cancer Treatment
September 20, 2019
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
September 16, 2019
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
August 28, 2019
Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
August 6, 2019
Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
August 6, 2019
The Sanofi Atopic Dermatitis drug Dupixent® (dupilumab) Revolutionizes Adolescent Care
July 29, 2019
Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019
July 29, 2019
Sanofi delivered solid growth in Q2 2019
July 26, 2019
Update on Zynquista™ (sotagliflozin) Type 2 Diabetes Phase 3 Program and Collaboration with Lexicon
July 26, 2019
Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
July 23, 2019
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
July 10, 2019
Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
July 2, 2019
Sanofi : Availability of the Pre-quarterly Results Communication
July 1, 2019
EC Approval: Libtayo® (cemiplimab) for Advanced Skin Cancer
June 28, 2019
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
June 27, 2019
Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
June 26, 2019
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
June 21, 2019
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
June 18, 2019
Sanofi and Google to develop new healthcare Innovation Lab
June 9, 2019
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
June 7, 2019
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
June 2, 2019
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
May 7, 2019
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
April 30, 2019
Sanofi: Annual General Meeting of April 30, 2019
April 26, 2019
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
April 26, 2019
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
April 26, 2019
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
April 26, 2019
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
April 8, 2019
Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
April 1, 2019
Sanofi: Availability of the Pre-quarterly Results Communication
March 22, 2019
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
March 15, 2019
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
March 13, 2019
Sanofi successfully prices EUR 2 billion of bond issues
March 8, 2019
Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
March 8, 2019
Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
March 1, 2019
Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
March 1, 2019
Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
February 25, 2019
Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
February 25, 2019
Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
February 12, 2019
Sanofi appoints Ameet Nathwani Chief Digital Officer
February 7, 2019
Sanofi delivers 2018 business EPS growth of 5.1% at CER
February 6, 2019
Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
February 6, 2019
Sanofi's Cablivi ® (caplacizumab-yhdp) : A New Era in acquired Thrombotic Thrombocytopenic Purpura (aTTP) Treatment
February 5, 2019
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
February 4, 2019
Sanofi : CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
January 30, 2019
Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
January 17, 2019
Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
January 11, 2019
Sanofi: Availability of the Pre-quarterly Results Communication
January 9, 2019
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
January 7, 2019
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs